Recent developments in next-generation sequencing (NGS) and tumour immunology have allowed the discovery that targeting the CTLA4, programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) receptors using therapeutic monoclonal antibodies [1] can unmask cancer to the immune system, facilitating its immune-mediated destruction. Here, PDCD1 is linked to neoplasm.